Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Source filing unavailable
Q2 2019 · —
Revenue$2.63B$2.63B+5.7% vs Q2 2018 Net Income$154.00M$154.00M−72.3% vs Q2 2018 EPS Diluted$0.11$0.11−72.5% vs Q2 2018 Gross Profit$1,873,000,000+7.0% Operating Income$384,000,000−2.0% Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
$292,000,000
N/M
Free Cash Flowderived$201,000,000N/M Margins · derivedGross margin71.2%+0.9 pt vs Q2 2018
Operating margin14.6%−1.1 pt vs Q2 2018
Net margin5.9%−16.4 pt vs Q2 2018